🏛️ Verified NIH Record • Updated 2025-05-27
Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease (NCT05115331)
1-2 PUNCH: Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease
🔵 Active, Not Recruiting Phase3 📋 Clinical Research Protocol Sponsor: University of Cincinnati
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized Phase III study evaluating the efficacy of hypofractionated and dose-escalated palliative radiation therapy in metastatic bone disease (MBD). Patients will be randomized 1:1 to the conventional (8 Gy in a single fraction) and experimental (16 Gy in 2 fractions) groups with baseline and subsequent assessment of both pain and quality of life metrics.
Who can join: Review the eligibility criteria below.
Location: University of Cincinnati — Cincinnati, Ohio
Age range: 18 Years
🧪 Interventions in This Study
- Experimental Radiation Dose (RADIATION)
- Conventional Radiation Dose (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Cincinnati — Cincinnati, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Metastatic Bone Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.